Phase II evaluation of metoprine in patients with non-small-cell lung carcinoma

G. R. Lynch, R. J. Gralla, E. S. Casper

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


A phase II study of metoprine in low dose and in high dose with citrovorum rescue was conducted in patients with non-small-cell lung carcinoma. There were no responses observed in the 36 patients studied, yielding a predicted true response rate of <9%. Thrombocytopenia was the dose-limiting toxicity of the low-dose regimen; there was also one episode of leukopenia and sepsis in this group. Although citrovorum rescue obviated hematologic toxicity in the high-dose regimen, mild to moderate neurological toxicity occurred at this dose. Metoprine does not appear to be a useful agent in non-small-cell lung carcinoma when used in the dose schedule employed in this study.

Original languageEnglish (US)
Pages (from-to)273-276
Number of pages4
JournalCancer clinical trials
Issue number3
StatePublished - 1981
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Phase II evaluation of metoprine in patients with non-small-cell lung carcinoma'. Together they form a unique fingerprint.

Cite this